Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter February 23, 2021

Free-thyroxine standardization: waiting for Godot while well serving our patients today

  • Luca Giovanella ORCID logo EMAIL logo

Corresponding author: Luca Giovanella, MD, PhD, Clinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Ente Ospedaliero Cantonale, Via A. Gallino 12, 6500 Bellinzona, Switzerland; and University Hospital and University of Zurich, Zurich, Switzerland, Phone: +41 91 811 86 72, Fax: +41 91 811 85 02, E-mail:

  1. Research funding: None declared.

  2. Author contributions: The author has accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: The author received research fees, speaker fees and participated in an advisory board of Roche Diagnostics, Rothkreutz, Switzerland.

References

1. Midgley, JE. Global FT4 Immunoassay Standardization. Response to: Kratzsch J et al. Global FT4 immunoassay standardization: an expert opinion review. Clin Chem Lab Med 2021;59:e223–4.10.1515/cclm-2021-0036Search in Google Scholar PubMed

2. Kratzsch, J, Baumann, NA, Ceriotti, F, Lu, ZX, Schott, M, van Herwaarden, AE, et al.. Global FT4 immunoassay standardization: an expert opinion review. Clin Chem Lab Med 2021;59:1013–23. https://doi.org/10.1515/cclm-2020-1696.Search in Google Scholar PubMed

3. Plebani, M, Giovanella, L. Reflex TSH strategy: the good, the bad and the ugly. Clin Chem Lab Med 2019;58:1–2. https://doi.org/10.1515/cclm-2019-0625.Search in Google Scholar PubMed

Received: 2021-02-13
Accepted: 2021-02-15
Published Online: 2021-02-23
Published in Print: 2021-05-26

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 19.4.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2021-0201/html
Scroll to top button